This study focuses on treating people with COVID-19 who have severely weakened immune systems. The research evaluates two medications: ibuzatrelvir, which is taken as a tablet by mouth, and remdesivir, which is given through a vein as an infusion. Some participants will receive ibuzatrelvir alone, some will receive both medications together, and others will receive placebo.
The purpose of this research is to determine how well ibuzatrelvir works when used alone or combined with remdesivir in treating COVID-19 symptoms and reducing the amount of virus in people with weakened immune systems. The study includes people who have received organ transplants, those with blood cancers, individuals who have received certain cancer treatments, or those taking medications that affect their immune system.
During the study, participants will receive the study medication for up to three days. They will be monitored for changes in their COVID-19 symptoms and the amount of virus in their body. The study will track whether participants need emergency care, hospital treatment, or experience other health problems related to COVID-19. The total study period is 38 days, during which participants will have regular check-ups to monitor their health and any side effects.



Belgium
Denmark
France
Germany
Greece
Slovakia
Spain
Sweden
The Netherlands